Clinical trial NCT06331715: Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mg
Official title: An Open Label, Balanced, Randomized, Two Treatments, Two Sequences, Two Periods, Single Dose, Crossover Bioequivalence Study of Palbociclib 125 mg Capsules (Iclos) and Ibrance (Palbociclib) 125 mg Capsules Pfizer in Healthy Subjects Under Fed Condition
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Bioequivalence
Keywords: palbociclib
Lead sponsor: Megalabs
Sponsor class: INDUSTRY
First posted: 2024-03-26
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: An open label, balanced, randomized, two treatments, two sequences, two periods, cross over, single dose, bioequivalence study of Palbociclib 125 mg Capsules of Iclos Uruguay S.A and IBRANCE® (Palbociclib) 125 mg Capsules of Pfizer Europe (Belgium) in healthy, adult, human subjects under fed condition.

Detailed description: 24 healthy subjects males and/or non pregnant, non breast feeding females will be randomized to receive either Test product (Palbociclib 125 mg Capsules of Iclos Uruguay S.A.) or Reference product (Ibrance® Palbociclib 125 mg Capsules of Pfizer Europe in healthy, adult, human subjects under fed condition. Trial design will be balanced, randomized, two treatments, two sequences, two periods, cross over, single dose, bioequivalence study of in healthy, adult, human subjects under fed condition to assess the bioequivalence between test and comparator formulations.

Statistical analysis will be performed on the Ln-transformed pharmacokinetic parameters using SAS® v 9.4. The analysis will include data from subjects who complete the study. If there are dropouts, no replacement will be done.

To establish bioequivalence of the test product with that of comparator product, 90% Confidence Interval (CI) for the ratio (Test/ Comparator) of Least Square Means of the log transformed PK parameters (Cmax and AUC0-72) must fall between 80.00% and 125.00%. Confidence Interval (CI) values will not be rounded off.

Eligibility criteria: Inclusion Criteria:

* Healthy male and/or non-pregnant, non-breast feeding female literate volunteers of 18 to 45 years (both years inclusive) with BMI of 18.50 - 30.00 Kg/m2 and weight \> 50 Kg.
* Healthy volunteers as evaluated by medical history, vitals and general clinical examination.
* Normal or clinically insignificant biochemical, hematological, urine and serology parameters.
* Normal or clinically insignificant ECG.
* Negative urine test for drugs of abuse and alcohol breath analysis for both males and females,
* Negative pregnancy test for females and do not plan to become pregnant during course of the study and for 03 months after completion of study.
* Volunteers who are willing to use acceptable methods of contraception during course of the study and for 03 months after completion of study.
* Volunteers who can give voluntary written informed consent and communicate effectively.

Exclusion Criteria:

* History of any major surgical procedure in the past 03 months.
* History of any clinically significant cardiac, gastrointestinal, respiratory, hepatic, renal, endocrine, neurological, metabolic, psychiatric and hematological disorders.
* History of chronic alcoholism/ chronic smoking/ drug of abuse.
* Volunteers with known hypersensitivity to Palbociclib or any of the excipients.
* History of consumption of tobacco containing products within 48 hours prior to proposed time of dosing
* Volunteer who are positive for hepatitis B surface antigen, anti-hepatitis C antibody, treponemal antibodies and human immunodeficiency virus (HIV 1\&2) antibodies.
* Present or past history of intake of drugs or any prescription drug or over the counter (OTC) drugs/ vaccines (including COVID 19 vaccines) within 14 days which potentially modify kinetics / dynamics of Palbociclib or any other medication judged to be clinically significant by the investigator.
* History of consumption of grapefruit and/or its products within 10 days prior to the start of study.
* Volunteer who had participated in any other clinical study or who had bled during the last 03 months before check-in.
* History of consumption of one or more of the below, 48 hours prior to dosing:

Xanthine containing food or drinks such as cola, chocolate, coffee or tea, citrus fruits or items (lime, lemon and orange), alcohol and any other food/beverage known to have interactions as deemed by the investigator

* History of difficulties in swallowing tablets/capsules.

Primary outcomes:
measure: AUC 0-t
timeFrame: 72 hours
measure: Cmax
timeFrame: 72 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Chennai
country: India
facility: Azidus Laboratories
Study officials:
affiliation: Azidus Laboratories
name: M Gowtham, MD
role: PRINCIPAL_INVESTIGATOR
References: